Human papillomavirus testing on self‐sampled cervicovaginal brushes: An effective alternative to protect nonresponders in cervical screening programs
Open Access
- 30 January 2007
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 120 (7) , 1505-1510
Abstract
Women not attending cervical screening programs are at increased risk of cervical cancer. We investigated in these nonresponders to what extent offering self‐sampling devices for cervicovaginal brushes for high‐risk human papillomavirus (hrHPV) testing would induce participation and, if so, what the yield of precursor (i.e. CIN2 or worse) lesions following self‐sampling would be. In addition, we assessed screening history of participants and costs per detected high‐grade CIN2 or worse (“CIN2+”) lesion in comparison to the regular program in the Netherlands. Nonresponders received a device for hrHPV testing (self‐sampling group, n = 2,546) or an extra recall for conventional cytology (control group, n = 284). The percentage of self‐sampling responders were compared with responders in the recall group. hrHPV positive self‐sampling responders were invited for cytology and colposcopy. CIN2+ yield and costs per detected CIN2+ were evaluated. Active response was higher in the self‐sampling than in the control group (34.2 vs. 17.6%; p < 0.001). hrHPV positive self‐sampling responders were less likely to have a prior screening history than screening participants (p < 0.001), indicating that they are regular nonresponders. hrHPV prevalence was similar (8.0 vs. 6.8%; p = 0.11), but CIN2+ yield was higher in self‐sampling responders compared to screening participants (1.67 vs. 0.97%; OR = 2.93, 95% CI 1.48–5.80; p = 0.0013). Costs per CIN2+ lesion detected via self‐sampling were in the same range as those calculated for conventional cytological screening (€8,836 vs. €7,599). Offering self‐sampling for hrHPV testing in nonresponders is an attractive adjunct to effectively increase population coverage of screening without the adverse effect of markedly increased costs per detected CIN2+ lesion.Keywords
This publication has 29 references indexed in Scilit:
- Cross-Sectional Comparison of an Automated Hybrid Capture 2 Assay and the Consensus GP5+/6+ PCR Method in a Population-Based Cervical Screening ProgramJournal of Clinical Microbiology, 2006
- High Concordance of Results of Testing for Human Papillomavirus in Cervicovaginal Samples Collected by Two Methods, with Comparison of a Novel Self-Sampling Device to a Conventional Endocervical BrushJournal of Clinical Microbiology, 2006
- Evaluation of cervical screening strategies with adjunct high‐risk human papillomavirus testing for women with borderline or mild dyskaryosisInternational Journal of Cancer, 2005
- The cervical cancer epidemic that screening has prevented in the UKThe Lancet, 2004
- The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996Journal of Clinical Pathology, 2004
- POBASCAM, a population‐based randomized controlled trial for implementation of high‐risk HPV testing in cervical screening: Design, methods and baseline data of 44,102 womenInternational Journal of Cancer, 2004
- GP5+/6+ PCR followed by Reverse Line Blot Analysis Enables Rapid and High-Throughput Identification of Human Papillomavirus GenotypesJournal of Clinical Microbiology, 2002
- Overview of important cervical cancer screening process values in European Union (EU) countries, and tentative predictions of the corresponding effectiveness and cost-effectivenessEuropean Journal of Cancer, 2000
- New technologies in cervical cytology screening: a word of cautionObstetrics & Gynecology, 1999
- Missed Opportunities for Cervical Cancer Screening of HMO Members Developing Invasive Cervical Cancer (ICC)Gynecologic Oncology, 1998